FINWIRES · TerminalLIVE
FINWIRES

Johnson & Johnson's Caplyta Has More Than $5 Billion Peak Sales Potential, UBS Says

By

Johnson & Johnson's (JNJ) positive phase 3 bipolar mania data and

consistent safety profile for Caplyta support more than $5 billion in peak sales potential, UBS said in a note emailed Tuesday.

UBS said it sees the readout as a meaningful positive for the broader Caplyta

franchise and noted effect size on efficacy as particularly noteworthy, while statistically significant separation from placebo as early as Day 3 could support broader use.

UBS said Caplyta's safety was consistent with its established profile, with dry mouth and nausea each reported in 7.9% of patients. The brokerage said it expects generic competition to remain limited beyond the next decade.

UBS maintained a buy rating on th stock with a $320 per share price target.

Price: $269.66, Change: $+0.19, Percent Change: +0.07%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA